NASDAQ:FPRX - Five Prime Therapeutics Stock Price, Price Target & More

Five Prime Therapeutics trades on the NASDAQ under the ticker symbol "FPRX."

Five Prime Therapeutics Inc (NASDAQ:FPRX) issued its earnings results on Tuesday, May, 8th. The biotechnology company reported ($0.63) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.55) by $0.08. The biotechnology company had revenue of $32.49 million for the quarter, compared to analyst estimates of $37.50 million. Five Prime Therapeutics had a negative return on equity of 44.36% and a negative net margin of 221.74%. View Five Prime Therapeutics' Earnings History.

7 analysts have issued 12-month price objectives for Five Prime Therapeutics' stock. Their predictions range from $17.00 to $60.00. On average, they anticipate Five Prime Therapeutics' stock price to reach $34.7143 in the next twelve months. View Analyst Ratings for Five Prime Therapeutics.

Some companies that are related to Five Prime Therapeutics include Clovis Oncology (CLVS), Xencor (XNCR), Corcept Therapeutics (CORT), Enanta Pharmaceuticals (ENTA), TESARO (TSRO), Heron Therapeutics (HRTX), Akcea Therapeutics (AKCA), Spectrum Pharmaceuticals (SPPI), Global Blood Therapeutics (GBT), Puma Biotechnology (PBYI), Insmed (INSM), Endo International (ENDP), ACADIA Pharmaceuticals (ACAD), Prestige Brands (PBH) and Akorn (AKRX).

Media headlines about FPRX stock have been trending somewhat negative this week, according to Accern Sentiment. The research firm scores the sentiment of press coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Five Prime Therapeutics earned a news impact score of -0.06 on Accern's scale. They also gave press coverage about the biotechnology company an impact score of 46.77 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.

Five Prime Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.56%), Victory Capital Management Inc. (3.04%), Dimensional Fund Advisors LP (2.96%), BB Biotech AG (2.78%), Rock Springs Capital Management LP (1.66%) and Northern Trust Corp (1.05%). Company insiders that own Five Prime Therapeutics stock include Francis Willard Sarena, Lewis T Williams, Peder Jensen and William R Ringo. View Institutional Ownership Trends for Five Prime Therapeutics.

FPRX stock was sold by a variety of institutional investors in the last quarter, including Eventide Asset Management LLC, Citigroup Inc., Spark Investment Management LLC and Russell Investments Group Ltd.. View Insider Buying and Selling for Five Prime Therapeutics.

FPRX stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Rock Springs Capital Management LP, BB Biotech AG, DekaBank Deutsche Girozentrale, Victory Capital Management Inc., Millennium Management LLC, UBS Group AG and State of Wisconsin Investment Board. View Insider Buying and Selling for Five Prime Therapeutics.

Shares of FPRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of FPRX stock can currently be purchased for approximately $17.31.

Five Prime Therapeutics has a market capitalization of $598.91 million and generates $39.51 million in revenue each year. The biotechnology company earns $-150,220,000.00 in net income (profit) each year or ($5.38) on an earnings per share basis. Five Prime Therapeutics employs 216 workers across the globe.

Five Prime Therapeutics' mailing address is 111 Oyster Point Boulevard, South San Francisco CA, 94080. The biotechnology company can be reached via phone at 415-365-5600.